Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TK1 | P04183 | 3/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14511225 | 1.00 | TK1 (0.34) | TK1 | |
| SCHEMBL20394057 | 0.92 | TK1 (0.37) | TK1 | |
| SCHEMBL20394055 | 0.92 | TK1 (0.37) | TK1 | |
| SCHEMBL28749276 | 0.92 | TK1 (0.37) | TK1 | |
| SCHEMBL28618584 | 0.89 | TK1 (0.39) | TK1 | |
| SCHEMBL28618582 | 0.89 | TK1 (0.39) | TK1 | |
| SCHEMBL5696121 | 0.89 | TK1 (0.39) | TK1 | |
| SCHEMBL9961264 | 0.86 | TK1 (0.37) | TK1 | |
| SCHEMBL14536634 | 0.84 | TK2 (0.32) | — | |
| SCHEMBL1097256 | 0.83 | TK1 (0.39) | TK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9464106-B2 | Oligonucleotides useful for detecting and analyzing nucleic acids of interest | EXIQON A/S (DK) | 2016-10-11 | — | — | US | disclosed |
| US-20120157333-A1 | OLIGONUCLEOTIDES USEFUL FOR DETECTING AND ANALYZING NUCLEIC ACIDS OF INTEREST | EXIQON A/S (DK) | 2012-06-21 | — | — | US | disclosed |
| US-20060147924-A1 | Population of nucleic acids including a subpopulation of lna oligomers | EXIQON A/S (DK) | 2006-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060147924-A1 | Population of nucleic acids including a subpopulation of lna oligomers | NSUN2, NCL, RNGTT | TK1 62/4885 |
| US-20120157333-A1 | OLIGONUCLEOTIDES USEFUL FOR DETECTING AND ANALYZING NUCLEIC ACIDS OF INTEREST | UPF1, DCLRE1B, SNRPA1 | TK1 660/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.